Lennart T. Mars

Lennart T. Mars

Auto-generated profile, based on publicly available information

Lennart T. Mars

INSERM UMR995, Laboratory of Neuroinflammation and Multiple Sclerosis, F-59000 Lille, France

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Immunity
Verified
Journal Article
Closed access
RLRoland S. Liblau
Roland S. Liblau
FWF.SUsan Wong
F.SUsan Wong
LMLennart T. Mars
Lennart T. Mars
PSPere Santamaria
Pere Santamaria

31 May 2009 in Nature Medicine
Verified
Journal Article
Closed access
GKGurumoorthy Krishnamoorthy
Gurumoorthy Krishnamoorthy
ASAmit Saxena
Amit Saxena
LMLennart T Mars
Lennart T Mars
HDHelena S Domingues
Helena S Domingues
RMReinhard Mentele
Reinhard Mentele
HWHartmut Wekerle
Hartmut Wekerle

1 August 2008 in The Journal of Immunology
Verified
Journal Article
Closed access
ASAmit Saxena
Amit Saxena
JBJan Bauer
Jan Bauer
TSTanja Scheikl
Tanja Scheikl
JZJacques Zappulla
Jacques Zappulla
MAMarc Audebert
Marc Audebert
MLMars Lt
Mars Lt
CD8 T cells are emerging as important players in multiple sclerosis (MS) pathogenesis, although their direct contribution to tissue damage is still debated. To assess whether autoreactive CD8 T cells can contribute to the pronounced loss of oligodendrocytes observed in MS plaques, we generated mice in which the model Ag influenza hemagglutinin is selectively expressed in oligodendrocytes. Transfer of preactivated hemagglutinin-specific CD8 T cells led to inflammatory lesions in the optic nerve, spinal cord, and brain. These lesions, associating CD8 T cell infiltration with focal loss of oligodendrocytes, demyelination, and microglia activation, were very reminiscent of active MS lesions. Thus, our study demonstrates the potential of CD8 T cells to induce oligodendrocyte lysis in vivo as a likely consequence of direct Ag-recognition. These results provide new insights with regard to CNS tissue damage mediated by CD8 T cells and for understanding the role of CD8 T cells in MS.

22 February 2011 in Brain
Verified
Journal Article
Open access
PDF file
NCNicolas Couturier
Nicolas Couturier
FBFlorence Bucciarelli
Florence Bucciarelli
RNRamil N. Nurtdinov
Ramil N. Nurtdinov
MDMarc Debouverie
Marc Debouverie
CLChristine Lebrun-Frenay
Christine Lebrun-Frenay
DBDavid Brassat
David Brassat
The tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations. However, the functional effect of this variant on disease pathogenesis remains unclear. This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls. Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2GC genotype with the disease-associated TYK2GG genotype. Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines. These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype. This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2. The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.

1 June 2000 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CMClaudia Mauri
Claudia Mauri
LMLennart T. Mars
Lennart T. Mars
MLMarco Londei
Marco Londei

3 December 2009 in Blood
Verified
Journal Article
Closed access
PDF file
NGNicolas Gaudenzio
Nicolas Gaudenzio
NENicolas Espagnolle
Nicolas Espagnolle
LMLennart T. Mars
Lennart T. Mars
RLRoland Liblau
Roland Liblau
SVSalvatore Valitutti
Salvatore Valitutti
EEEric Espinosa
Eric Espinosa
It has been suggested that mast cells might serve, under certain circumstances, as antigen-presenting cells (APCs) for T cells. However, whether cognate interactions between mast cells and class II–restricted CD4+ T cells actually occur is still an open question. We addressed this question by using peritoneal cell–derived mast cells (PCMCs) and freshly isolated peritoneal mast cells as APC models. Our results show that in vitro treatment of PCMCs with interferon-γ and interleukin-4 induced surface expression of mature major histocompatibility complex class II molecules and CD86. When interferon-γ/interleukin-4–primed PCMCs were used as APCs for CD4+ T cells, they induced activation of effector T cells but not of their naive counterparts as evidenced by CD69 up-regulation, proliferation, and cytokine production. Confocal laser scanning microscopy showed that CD4+ T cells formed immunological synapses and polarized their secretory machinery toward both antigen-loaded PCMCs and freshly isolated peritoneal mast cells. Finally, on cognate interaction with CD4+ T cells, mast cells lowered their threshold of activation via FcϵRI. Our results show that mast cells can establish cognate interactions with class II–restricted helper T cells, implying that they can actually serve as resident APCs in inflamed tissues.